Apolo AB, Nadal R, Girardi DM, et al. - In this study, the safety and efficacy of cabozantinib and nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) were examined in patients with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies. The preliminary aim was to develop a recommended phase II dose (RP2D). The objective response rate, progression-free survival, duration of response, and overall survival were considered as secondary objectives. Researchers included a total of 54 patients at eight dose levels with a median follow-up time of 44.6 months; data cutoff was January 20, 2020. It was reported that in patients with mUC and other GU tumors, caboNivo and CaboNivoIpi illustrated manageable toxicities with durable responses and encouraging survival. In addition, multiple phase II and III trials are ongoing for these combinations.